

# THE PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY

VOLUME 5

2003

SUPPLEMENT 3

S U P P L E M E N T

**Using Atypical Antipsychotics  
in Primary Care, 1:  
Evidence and Clinical Strategies**

THE OFFICIAL JOURNAL OF THE ASSOCIATION OF MEDICINE AND PSYCHIATRY

© COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. © COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC.

To obtain credit, read the material and complete the Posttest and Registration Form on pages 38–40.

**CME OBJECTIVES**

After completing this educational activity, participants should be able to:

- Describe primary care populations in whom atypical antipsychotic treatment would be appropriate
- Describe the pharmacology that characterizes an atypical antipsychotic
- Discuss appropriate dosing strategies to maximize optimal safety and efficacy of atypical antipsychotics
- Review the literature on using atypical antipsychotics in psychosis and mood and anxiety disorders

**STATEMENT OF NEED AND PURPOSE**

Atypical antipsychotics are increasingly being used for special populations such as children and the elderly and for new indications, including severe anxiety and affective disorders. This educational activity is designed to meet the needs of primary care physicians who have requested information about the use of atypical antipsychotics in their practice. There are no prerequisites for this activity.

**ACCREDITATION STATEMENT**

Physicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**CREDIT DESIGNATION**

Physicians Postgraduate Press, Inc. designates this educational activity for up to 4 Category 1 credits toward the AMA Physician's Recognition Award. Each participant should claim only those credits that he/she actually spent in the educational activity.

**DATE OF ORIGINAL RELEASE/REVIEW**

This Supplement was published in May 2003 and is eligible for CME credit through May 31, 2004. The latest review of this material was April 2003.

**FACULTY**

**Chair:** Joseph A. Lieberman III, M.D., M.P.H. **Faculty:** Larry Culpepper, M.D., M.P.H.; Stephen R. Marder, M.D.; Robert E. Rakel, M.D.; Zafar A. Sharif, M.D.; Stephen M. Stahl, M.D., Ph.D.

**FACULTY DISCLOSURE**

In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this CME activity were asked to complete a full disclosure statement. The information received is as follows:

- Dr. Lieberman is a consultant for Abbott, Bristol-Myers Squibb, Forest, Janssen, Novartis, Novo Nordisk, Organon, Eli Lilly, Pfizer, Pharmacia, and Sanofi-Synthelabo.
- Dr. Culpepper is a consultant for Abbott, Forest, Janssen, Eli Lilly, Pharmacia, Pfizer, and Wyeth.
- Dr. Marder is a consultant for, has received grant/research support and honoraria from, and is a member of the speakers/advisory boards for Janssen, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, and Pfizer.
- Dr. Sharif is a consultant for Janssen and has received grant/research support and honoraria from and is a member of the speakers/advisory boards for Janssen and Bristol-Myers Squibb.
- Dr. Stahl is a consultant for and has received honoraria from Asahi Beer Pharmaceutical Co., Abbott, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cephalon, Cypress Bioscience, Eli Lilly, Pierre Fabre, Forest, GlaxoSmithKline, Janssen, Lorex Pharmaceuticals, Lundbeck, Neurocrine Biosciences, Novartis, Organon, Parke-Davis, Pfizer, Pharmacia, Roche Pharmaceuticals, Sanao, Sanofi-Synthelabo, Searle, Solvay, Sumitomo, Takeda Abbott, Watson Pharmaceuticals, Wyeth, and Yamanouchi; has received grant/research support from Asahi Beer Pharmaceutical Co., AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cephalon, Cypress Bioscience, Pierre Fabre, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Lundbeck, Organon, Parke-Davis, Pfizer, Pharmacia, Sanofi-Synthelabo, Solvay, Watson Pharmaceuticals, Wyeth, and Yamanouchi; and is a member of the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Lundbeck, Organon, Parke-Davis, Pfizer, Pharmacia, Sanofi-Synthelabo, Solvay, Watson Pharmaceuticals, and Wyeth.
- Dr. Rakel has no significant commercial relationship to disclose relative to his presentation.

**DISCLOSURE OF OFF-LABEL USAGE**

In this Supplement, faculty may be presenting investigational information about pharmaceutical agents that is outside U.S. Food and Drug Administration–approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. Please consult the paragraph titled “Disclosure of Off-Label Usage” at the end of each article for a complete listing of off-label or investigational uses. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

**ACKNOWLEDGMENT**

The material in this Supplement was presented at the planning roundtable “Using Atypical Antipsychotics in Primary Care,” which was held June 2–4, 2002, in Washington, D.C. This Supplement was independently developed by the Physicians Postgraduate Press, Inc. Office of Continuing Medical Education pursuant to an unrestricted educational grant from Janssen Pharmaceutica, L.P. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the CME provider and publisher or the commercial supporter.

# THE PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY

VOLUME 5

2003

SUPPLEMENT 3



*The Primary Care Companion to The Journal of Clinical Psychiatry* (ISSN 1523-5998) is published bimonthly by Physicians Postgraduate Press, Inc. Address correspondence to *The Primary Care Companion*, 3175 Lenox Park Blvd., Suite 409, Memphis, TN 38115; phone inquiries to (901) 273-2753; e-

mail to [primarycare@psychiatrist.com](mailto:primarycare@psychiatrist.com). Individual subscription rates: U.S., \$70.00; international, \$110.00; student (U.S.), \$50.00. Single copies of the *Companion* or supplements are \$20 U.S. and \$25 international (including postage and handling); prepayment is requested.

*The Primary Care Companion to The Journal of Clinical Psychiatry* is owned and published by Physicians Postgraduate Press, Inc., 3175 Lenox Park Blvd., Suite 409, Memphis, TN 38115. All articles appearing in this publication, including editorials, letters, and book reviews, represent the opinions of the authors and do not necessarily reflect the official policy or opinions of Physicians Postgraduate Press, Inc. or the institution with which the author is affiliated, unless this is clearly specified.

Physicians Postgraduate Press, Inc. disclaims any liability to any party for the accuracy, completeness, or availability or any and all Physicians Postgraduate Press, Inc. publications and other material, or for any damages arising out of the use or non-use of this publication, and any and all Physicians Postgraduate Press, Inc. publications (and other material), and any information contained therein.

*The Primary Care Companion to The Journal of Clinical Psychiatry* requires the express transfer of copyright to Physicians Postgraduate Press, Inc., so that the author(s) and Physicians Postgraduate Press, Inc. are protected from misuse of copyrighted material. All submissions must be accompanied by a copyright transfer signed by all authors.

A \$5.00 fee per article for photocopying material appearing in the *Companion* is payable to Physicians Postgraduate Press, Inc. This fee is waived in lieu of a specific charge to be determined on a case-by-case basis for classroom and library use; it is the responsibility of the institution or individual to obtain permission for such use.

Acceptance of any and all advertising in this publication, or any other material published by Physicians Postgraduate Press, Inc. does not imply endorsement by Physicians Postgraduate Press, Inc.

Visit our Web site at [www.PrimaryCareCompanion.com](http://www.PrimaryCareCompanion.com).

© Copyright 2003 Physicians Postgraduate Press, Inc. All rights reserved.

## BOARD OF EDITORS

Editor in Chief ..... Larry Culpepper, M.D., M.P.H.  
Deputy Editor ..... Donna B. Greenberg, M.D.

## EDITORIAL BOARD

Robert L. Barkin, M.B.A., Pharm.D.	M. Kevin O'Connor, M.D.
Pamela D. Connor, Ph.D.	Dean Schuyler, M.D.
Caroline Carney-Doebbeling, M.D.	L. Lee Tynes, M.D., Ph.D.
Bradford L. Felker, M.D.	Sumer Verma, M.D.
Kevin S. Ferentz, M.D.	Christian G. Wolff, M.D.
W. Clay Jackson, M.D., Dip.Th.	Lawson R. Wulsin, M.D.
Prakash S. Masand, M.D.	

## CME ADVISORY BOARD

Michael H. Ebert, M.D., Chair	Alan J. Gelenberg, M.D.
Richard C. Shelton, M.D., Vice Chair	Radwan F. Haykal, M.D.
Benjamin L. Beatus, Jr., M.D.	Paul King, M.D.
E. Sherwood Brown, Ph.D., M.D.	Joseph A. Lieberman, III, M.D., M.P.H.
Stephanie Cavanaugh, M.D.	Elizabeth H. B. Lin, M.D., M.P.H.
Lawrence J. Cohen, Pharm.D.	Frank W. Ling, M.D.
Larry Culpepper, M.D., M.P.H.	J. Sloan Manning, M.D.
John M. Downs, M.D.	Meir Steiner, M.D., Ph.D.

**FOUNDING EDITOR** ..... J. Sloan Manning, M.D.

## PUBLICATION STAFF

Publisher	John S. Shelton, Ph.D.
Publisher Emeritus	Irving Shelton
Assistant Publisher	Judy Beach
Permissions Editor	Maureen Bunner-Hunsucker
Dir. Business Development	Lee Harrington, R.Ph.
Managing Editor	Meg M. Waters
Deputy Managing Editor	Kathryn Hedges
Assistant Editor	Sarah L. Brownd
Assistant Editor	Sallie L. Gatlin
Assistant Editor	Erin Mullin Hanski
Assistant Editor	David M. Twombly
Senior Proofreader	Kathy E. Shassere
Proofreader	David Spicer
Publications Manager	C. J. Firestone
Publications Coordinator	Anna Kwapien
Production Coordinator	Diana L. Baessler
Production Assistant	Juliet Douglas
Media Director	Faye M. Green
Print Media Manager	Erik Adamec
Electronic Media Manager	F. Grant Whittle, Ph.D.
Journal Media Manager	Sara G. Amelang
CME Director	Jane B. Eckstein
Assistant CME Director	Becky Brown Derych
CME Coordinator	Diane Brunner
CME Assistant	Susan Bedford
Project Manager	Jennifer G. Alessi
Project Manager	Elizabeth Boone
Project Associate	Apryl M. Cox
Project Assistant	Susan K. Beaton
Project Assistant	K. L. Cox
Director of Circulation	Sharon Landers
Circulation Coordinator	Dianne Ware

---

# THE PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY

VOLUME 5

2003

SUPPLEMENT 3

---

## ARTICLES

---

- 3 The Use of Antipsychotics in Primary Care.  
*Joseph A. Lieberman III*
- 9 Describing an Atypical Antipsychotic:  
Receptor Binding and Its Role in Pathophysiology.  
*Stephen M. Stahl*
- 14 Overview of Safety and Tolerability of  
Atypical Antipsychotics Used in Primary Care.  
*Zafar A. Sharif*
- 22 Evidence for Using Atypical Antipsychotics in Psychosis.  
*Stephen R. Marder*
- 27 Evidence for Using Atypical Antipsychotics  
in Mood and Anxiety Disorders.  
*Larry Culpepper*
- 33 The Role of Atypical Antipsychotics in Depression  
in Primary Care.  
*Larry Culpepper and Robert E. Rakel*

---

## CME SECTION

---

- 38 Instructions and Posttest.
- 40 Registration Form and Evaluation.